NAD+ Side Effects: What Is Known and What Is Not
Summary: Two different gaps sit behind this question, and merging them produces a reassuring answer that the evidence does not support.
This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.
NAD+ side effects cannot be listed the way an approved medicine's can, and the reason divides into two halves that are routinely merged into one comforting sentence.
The first half is that a considerable amount of human safety information exists in this field, collected in trials of oral precursors, nicotinamide riboside and nicotinamide mononucleotide, taken as capsules. The second half is that injected and infused NAD+ has a far thinner record, no approval anywhere, and therefore no compiled adverse effect list produced by anyone with an obligation to produce one.
Merge those and you get: NAD is well studied in humans and well tolerated. Both clauses can be sourced. The sentence is still wrong about the product a reader is asking about, and it is the most common answer an NAD+ side effects search returns.
Where readers actually buy it
Ascension Peptides — NAD+
Research-grade NAD+, tested by two outside labs and shipped from the US. The code below takes half off the vial.
Quoted per 100 mg because NAD+ is dosed in hundreds of milligrams, not the single milligrams a peptide vial holds. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Batch certificates from two independent labs
- Free shipping over $250
- Ships same day if ordered before 2pm CST
Sold for laboratory research only and not for human consumption. These are affiliate links: we may earn a commission at no cost to you, and it does not change what we recommend. Prices checked August 20, 2026.
Splitting the NAD+ side effects question in two
Ask the question about a capsule and you are asking about an intervention that has been through controlled human trials, where participants were monitored and adverse events were recorded as part of the study design. Any specific answer still has to name which precursor and which trial population, but the category of evidence exists.
Ask it about an intravenous infusion or a self administered injection and you are asking about a different exposure. Different route, different speed of delivery, different concentrations reaching the blood, and a much smaller controlled literature to draw on. The honest answer for that version of the question is that the safety profile is not characterised in the way the phrase side effect list implies.
Keeping the two apart is not pedantry. It is the difference between an answer supported by data and an answer borrowed from an adjacent product.
Sources ranked by what they could catch
| Source | Intervention and route | What it can register | What it cannot |
|---|---|---|---|
| Controlled trials of oral precursors | NR or NMN, oral, in humans | Adverse events recorded systematically during the study | Anything about intravenous or injected NAD+ |
| Cell and animal studies of NAD biology | Various, in mice and cell culture | Effects on cells and rodents under laboratory conditions | Whether a human would feel or suffer anything |
| Infusion clinic experience | NAD+, intravenous, in humans | Immediate reactions the staff happen to see | Anything delayed, and anything the clinic does not publish |
| User accounts online | Usually NAD+, injected or infused, in humans | That someone experienced something and chose to say so | Frequency, attribution, and everyone who did not post |
| Regulatory safety reporting | Approved medicines only | Harms after launch, gathered under legal obligation | Nothing here. There is no approved product to report against |
The last row is the important one, and it is empty for a structural reason rather than a reassuring one.
The missing machinery is a mailbox, not a laboratory
When an approved medicine causes an unexpected problem, there is somewhere for that to go. Regulators run reporting systems, prescribers and patients submit reports, manufacturers are legally obliged to forward what they learn, and the accumulated signal is reviewed. Labels get updated years after launch because of it. That system is unglamorous, it is slow, and it is the main way rare harms are ever discovered.
Injected NAD+ has no place in that system, because nothing has been approved. There is no product licence to attach a report to and no manufacturer with a legal duty to collect one. A person harmed by an unregulated infusion in a wellness clinic has no obvious channel through which that fact enters any dataset, and if they never connect the event to the infusion, it does not enter one at all.
This is why the absence of a documented side effect list should not be read as an absence of side effects. Nobody has been counting. A quiet record produced by nobody counting looks exactly like a quiet record produced by nothing happening, and from outside the two are indistinguishable.
The lore about slowing the drip
Anyone who reads accounts of these infusions encounters the same practical folklore: that the experience during the infusion is unpleasant for some people, and that the response is to slow the rate.
Take that seriously as what it is. It is not a counted finding, it has no denominator, and it comes from the same commercial setting that has no reason to publish it systematically. What it does establish is that the rate of delivery is doing something noticeable in humans, which is information about the exposure even without a formal study behind it.
It also shows how the word dosage fails here. A quantity delivered slowly and the same quantity delivered quickly are different exposures, and a discussion that reports only the total has omitted the variable the folklore is entirely about.
What the animal and cell work can and cannot detect
A large amount of NAD research has been done in mice and in cell culture, and it is worth being precise about what that work contributes to a safety question.
In cells, an experiment can show that a compound is toxic to a cell line at a concentration, or that it is not. That is real information about cells in a dish under defined conditions. It does not describe what happens in a whole animal with a circulation, a liver and a kidney, let alone in a person.
In mice, an experiment can register weight loss, visible distress, organ changes at post mortem and death. Those are the harms an animal study is built to catch. What it cannot catch is everything that requires a subject who can describe it. A mouse cannot report nausea, headache, a change in mood, poor sleep, or the sensation that something feels wrong. Those are among the most common reasons humans stop taking things, and an entire species of evidence is blind to them.
So even a clean animal record leaves the human side effect question largely open, and animal work is generally the least relevant evidence for the outcomes people search for when they type this question.
Risks that have nothing to do with the molecule
A category of risk here is independent of NAD+ pharmacology and would apply to any substance delivered the same way.
Anything entering a vein bypasses every barrier the body has. That places sterility, technique and the cleanliness of the equipment among the most important variables in the whole procedure, and it makes an intravenous route categorically different from swallowing a capsule regardless of what is in the bag. Self injection at home adds the reconstitution step, performed by an untrained person with materials of unverified sterility.
Then there is identity. Material sold as a research chemical carries no independent assay of what it contains or at what concentration. A side effect from a contaminant, a wrong concentration or a different substance entirely would be attributed by the person experiencing it to NAD+, because that is what the label said. This is a general problem with unregulated supply and it is the reason harms in this space are difficult to attribute even in principle.
Caution that does not depend on a documented harm
It is possible to hold a cautious position without claiming that anything specific has been proven dangerous, and that is the honest position to hold here.
The reasoning runs: the safety data that exists mostly concerns a different intervention by a different route. No regulator has reviewed the injected form for any use. No system is collecting harms. The material is of unverified content. Individually each of these is a gap. Together they describe a situation in which a person cannot know what happened to other people who did the same thing, because nobody recorded it.
An NAD+ side effects list that nobody compiled is not the same as a short one. That is a reason for caution grounded in the structure of the evidence rather than in a scare story, and it does not require anyone to claim the compound is harmful.
Risk questions, answered as plainly as the evidence allows
- Is injected NAD+ well tolerated?
- Nobody is in a position to say. The phrase implies a counted safety record, and for this route and this product no such record exists. Reports from clinics and users describe experiences, but they have no denominator and no independent attribution.
- Precursor trials looked fine. Does that not reassure me?
- Only about precursors taken by mouth. Route determines the exposure, and a capsule converted inside the body is a different event from a bag delivered into a vein. Transferring the reassurance is the exact error this article exists to name.
- Why do vendors describe it as having no side effects?
- Because nothing has been documented, and undocumented is being reported as absent. A seller has no obligation to distinguish those and every commercial reason not to.
- Are the risks different in a clinic versus at home?
- A clinic adds trained staff, controlled conditions and someone present if an immediate reaction occurs, which is not nothing. It does not add an approval, a label, verified material in every case, or a channel through which what happens to you gets recorded anywhere.
- What should I do if I have already had infusions?
- Tell a clinician what you received, by what route, and roughly when. They cannot consult a label that does not exist, but they can interpret symptoms with your history in front of them and exclude other causes, which is more than any page can do for you.